Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent ...
Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...
“KRRO-110 has the potential to treat both liver and lung manifestations of AATD, and we are committed to addressing the unmet need and advancing this potentially best-in-class therapy for people ...
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
Todd Chappell, Chief KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to ...
Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).
Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...
Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results